Clinical trials: Metastatic Neoplasm
Solid Tumor
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to evaluate the safety, tolerability, and PK of IGM-7354 in participants with relapsed and/or refractory tumors.
- Trial name
- NCT05702424
- Testing
- IGM-7354
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- IGM Biosciences, Inc.
Sarcoma
NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
This pilot, phase I trial studies the safety of cancer-testis antigen (NY-ESO-1)-specific T cells (a type of immune cell) in treating patients with NY-ESO-1-expressing sarcomas that have spread to other places in the body and are…
- Trial name
- NCT02319824
- Testing
- Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Laboratory Biomarker Analysis, Palliative Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center
Head and Neck Cancer, Unknown Primary Cancer
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.
- Conditions
- Head and Neck Cancer, Unknown Primary Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05576974
- Testing
- Pegsitacianine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Neoplasms
A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours
Dichloroacetate (DCA) is a small molecule that has been used for years to treat lactic acidosis and rare metabolic disorders in humans. Further testing now shows that it may suppress the growth of human cancer cells.
- Trial name
- DCA (NCT00566410)
- Testing
- Dichloroacetate
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- AHS Cancer Control Alberta
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer, Advanced Prostate Cancer
European Registry of Next Generation Imaging in Advanced Prostate Cancer
The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and…
- Conditions
- Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
- Trial name
- RING (NCT06866782)
- Testing
- Imaging
- Where
- 24 sites in Belgium, France and 6 more
- Volunteers
- 600 people
- Sponsor
- Fundacio Puigvert
Renal Cell Cancer
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
This exploratory clinical study is designed to obtain pre-therapeutic imaging assessments in 20 evaluable patients with metastatic renal cell cancer (RCC) and an early post therapy assessment at baseline and at various early time…
- Trial name
- NCT00694096
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Penile Squamous Cell Carcinoma Stage IV
Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)
Penile cancer is an uncommon disease, with devastating physical and psychological effects on patients. Penile carcinoma even in advanced stages is responsive to several chemotherapeutic agents.
- Trial name
- PAZOPEN-SOGUG (NCT02279576)
- Testing
- Pazopanib, Paclitaxel
- Where
- 8 sites in Spain
- Volunteers
- 4 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Metastatic Colorectal Cancer
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
The purpose of the study is to evaluate the safety and efficacy of FOLFIRI (Irinotecan, Leucovorin and 5 Fluorouracil) chemotherapy when combined with sunitinib or FOLFIRI chemotherapy without adding sunitinib as the first line…
- Trial name
- NCT00457691
- Testing
- 5 fluorouracil, irinotecan, levo- leucovorin
- Where
- 132 sites in Argentina, Australia and 32 more
- Volunteers
- 768 people
- Sponsor
- Pfizer
Soft Tissue Sarcoma
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with…
- Trial name
- PICASSO III (NCT01168791)
- Testing
- Palifosfamide-Tris, doxorubicin
- Where
- 161 sites in United States, Argentina and 19 more
- Volunteers
- 447 people
- Sponsor
- Alaunos Therapeutics
Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC.
- Trial name
- SELECT-3 (NCT01809210)
- Testing
- selumetinib, gemcitabine, cisplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Melanoma
Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma
Mucosal melanoma is rare and associated with extremely poor prognosis.No effective treatment for advanced mucosal melanoma patients.Investigators conducted a randomized phase II study in patients with previously untreated…
- Trial name
- NCT02023710
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- 3 sites in China
- Volunteers
- 182 people
- Sponsor
- Peking University Cancer Hospital & Institute
Pain
Single-fraction IMRT Versus External Beam Radiotherapy for Patients With Spine Bone Metastases
This study is a prospective, randomized, monocentre, controlled explorative study in the parallel-group design to determine the pain relief after RT of patients with spinal bone metastases.
- Trial name
- SMART (NCT02358720)
- Testing
- Arm A, Arm B
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Heidelberg University
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
This phase I/II trial is studying the side effects of biological therapy and to see how well it works in treating patients with advanced myelodysplastic syndrome, chronic myeloid leukemia, acute myeloid leukemia, or acute…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00052520
- Testing
- therapeutic allogeneic lymphocytes, aldesleukin, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fred Hutchinson Cancer Center
Colorectal Cancer, Head and Neck Cancer
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis
- Trial name
- NCT00908024
- Testing
- BMS-754807, cetuximab (Erbitux®)
- Where
- 5 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer Survivors
Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer
The goal of this clinical trial is to assess the feasibility of an 8-week aerobic exercise program and its effect on arterial function in breast cancer survivors.
- Trial name
- NCT07517224
- Testing
- Aerobic Exercise
- Volunteers
- 40 people
- Sponsor
- Loyola University
Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of lapatinib when given together with dabrafenib in treating patients with thyroid cancer that cannot be removed by surgery and has not responded to previous treatment…
- Trial name
- NCT01947023
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
This multicenter, Phase Ib study is an open label, dose escalation, three-arm study evaluating the safety, tolerability, pharmacokinetics, and activity of oral (PO) GDC 0941 administered in combination with either intravenous…
- Trial name
- NCT00928330
- Testing
- GDC-0941, Trastuzumab, trastuzumab-MCC-DM1
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
This study aimis at detecting the genomic changes of ctDNA in patients of RAS and BRAF wild-type mCRC, who failed after first line treatment containing cetuximab.
- Trial name
- NCT04831528
- Testing
- Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others
- Volunteers
- 100 people
- Sponsor
- Fudan University
Colorectal Cancer Liver Metastasis
FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colorectal cancer patients with liver metastasis who have not received prior treatment.
- Trial name
- NCT06801665
- Testing
- FMT+QL1706+Bevacizumab+XELOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hua Jiang
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.